Peptide News Digest

Ozari Health Telehealth $86/mo, Avacta AVA6103 FOCUS-01, MetaVia DA-1726 ADA, PCAC February 2027, TerminaTOR Nuclear mTORC1, BSR Compounded GLP-1 Supply Down 90%

Ozari Health telehealth $86/mo, Avacta AVA6103 FOCUS-01 Phase 1, MetaVia DA-1726 ADA, PCAC Feb 2027, TerminaTOR mTORC1, chiral peptide-drug conjugates.

10 stories · Covering industry, clinical-trials, regulatory, research

Editor's Note

Tuesday digest split between fresh launches, ASCO/ADA-bound late-breakers, and a regulatory calendar update. On the launch side, Ozari Health opened a nationwide telehealth platform Monday with compounded semaglutide starting at $86/month and compounded tirzepatide at $120/month — pharmacy partners include Hallandale and VialsRX, with branded Wegovy/Ozempic/Mounjaro/Zepbound also available via the same channel. Avacta posted unaudited 2025 preliminary results on Tuesday and disclosed first-patient dosing in FOCUS-01, a Phase 1 trial of AVA6103 (the second pre|CISION-enabled candidate, a FAP-activated exatecan peptide-drug conjugate) in March 2026. MetaVia confirmed Monday that three late-breaking abstracts have been accepted at ADA 2026 (June 5-8 New Orleans): DA-1726 (a once-weekly subcutaneous oxyntomodulin analog GLP1R/GCGR dual agonist for obesity and MASH) and vanoglipel (DA-1241, a first-in-class GPR119 agonist evaluated as monotherapy and in combination with resmetirom for MASH and metformin for T2D). On the regulatory side, the FDA confirmed a second PCAC meeting before the end of February 2027 to review five additional peptides for the 503A bulks-list — GHK-Cu (injectable), Melanotan II, Cathelicidin LL-37, Dihexa acetate, and Mechano Growth Factor Pegylated (PEG-MGF). BSR Intelligence's mid-May briefing quantified the compounding-segment compression: compounded semaglutide shipments are down 90% year-over-year and tirzepatide down 34%, alongside the persistent counterfeit-purity problem (5-75% range, lead 10x safety limits) that has shadowed the research-peptide supply chain since 2018. Three non-GLP-1 research items round out the cycle: Nature Chemical Biology May 2026 reported a genetically encoded peptide mTORC1 inhibitor (TerminaTOR) that reveals nuclear mTORC1 as a distinct transcription-regulating compartment driving cancer cell proliferation; Nature Communications May 13 reported chiral engineering of tripeptide-drug conjugates that controls phase behavior between liquid-liquid phase separation and β-sheet-rich hydrogels; and SNS Insider's May 19 peptide synthesis market report projects $1.89B by 2035 anchored on the Bachem/PolyPeptide/CordenPharma SPPS capacity build-out.

Industry

Ozari Health Launches Nationwide Compounded GLP-1 Telehealth Platform (May 19): Semaglutide $86/Month + Tirzepatide $120/Month, Hallandale + VialsRX Pharmacy Partners

Ozari Health, a New York-based telehealth company, launched a nationwide platform on Tuesday May 19, 2026 offering compounded semaglutide starting at $86/month and compounded tirzepatide starting at $120/month, with branded options (Wegovy, Ozempic, Mounjaro, Zepbound) available through the same channel. Patients complete an online intake, get evaluated by state-licensed providers, and receive prescriptions filled by partner compounding pharmacies including Hallandale Pharmacy and VialsRX — the multi-pharmacy partner structure differentiates Ozari from telehealth platforms that work with a single compounding partner. Ozari pricing sits at the floor of the compounded GLP-1 market; comparable platforms (Sesame, Henry Meds, Wisp) range $99-249/month for compounded semaglutide. The launch lands as the FDA's April 30, 2026 proposal to exclude semaglutide, tirzepatide, and liraglutide from the 503B bulks list (comments closing June 29) puts long-term compounding-pharmacy access in question.

#ozari-health #compounded-glp-1 #telehealth #compounded-semaglutide #compounded-tirzepatide #hallandale-pharmacy #vialsrx
Clinical Trials

Avacta Unaudited 2025 Preliminary Results (May 19): FOCUS-01 First Patient Dosed March 2026 in Phase 1 AVA6103 (FAP-Exatecan pre|CISION-Enabled PDC)

Avacta Therapeutics reported unaudited preliminary results for the 12 months ended December 31, 2025 on Tuesday May 19, 2026, and disclosed that the first patient received treatment in FOCUS-01 — the Phase 1 clinical trial of AVA6103, a FAP-activated exatecan peptide-drug conjugate — in March 2026. AVA6103 is the second pre|CISION-enabled candidate in the Avacta clinical pipeline, after AVA6000 (FAP-Dox, which has Phase Ia/Ib data scheduled at ASCO 2026 in salivary gland cancers). The pre|CISION platform attaches a peptide tetrazolyl moiety cleaved by FAP (fibroblast activation protein) overexpressed in cancer-associated fibroblasts, allowing systemic administration of cytotoxic payloads without the dose-limiting toxicity that constrains free exatecan. FOCUS-01 is enrolling adults with advanced solid tumors. AVA6103 expands the platform from doxorubicin (in AVA6000) to exatecan — a topoisomerase I inhibitor with potency advantages in HER2-low and triple-negative breast cancer.

#avacta #ava6103 #fap-exatecan #focus-01 #peptide-drug-conjugate #precision-platform #phase-1
Clinical Trials

MetaVia ADA 2026 Late-Breaking Abstracts Confirmed (May 18): DA-1726 Oxyntomodulin Analog Phase 1 Part 3 + Vanoglipel (DA-1241) GPR119 Combination Posters June 7

MetaVia confirmed Monday May 18 that three late-breaking abstracts have been accepted at the ADA 2026 Scientific Sessions (June 5-8 New Orleans). DA-1726 is a once-weekly subcutaneous oxyntomodulin analog functioning as a GLP-1R/GCGR dual agonist for obesity and MASH; Phase 1 Part 3 higher-dose titration results will be presented, with full Phase 1 trial data expected in Q4 2026. Vanoglipel (DA-1241) is a first-in-class GPR119 agonist that promotes endogenous release of GLP-1, GIP, and PYY from the gut; the ADA poster covers synergistic preclinical effects in combination with resmetirom (Madrigal's MASH therapy) and with metformin for type 2 diabetes. The three-poster slate positions MetaVia as one of several mid-cap obesity-pipeline names with clinical data inflections clustered into the ADA + ASCO + EASD 2026 calendar.

#metavia #da-1726 #vanoglipel #da-1241 #oxyntomodulin #gpr119 #ada-2026 #phase-1
Regulatory

FDA Confirms Second PCAC Meeting Before End of February 2027 — GHK-Cu (Injectable), Melanotan II, Cathelicidin LL-37, Dihexa Acetate, PEG-MGF for 503A Bulks-List Review

The FDA confirmed the Pharmacy Compounding Advisory Committee will convene a second meeting before the end of February 2027 to review five additional peptides for potential 503A Bulk Drug Substances List inclusion: GHK-Cu (injectable formulation specifically — topical/cosmetic remains separate), Melanotan II, Cathelicidin (LL-37), Dihexa acetate, and Mechano Growth Factor Pegylated (PEG-MGF). The February 2027 meeting follows the July 23-24, 2026 PCAC that will review seven peptides (BPC-157, KPV, TB-500, MOTs-C on Day 1; Emideltide/DSIP, Semax, Epitalon on Day 2). Compounding pharmacies cannot legally compound these five peptides until the PCAC review concludes and the FDA issues a final determination — a 6-12 month timeline post-meeting. The peptide-specific indications under review span aesthetic dermatology (GHK-Cu, Melanotan II), antimicrobial activity (LL-37), neuroprotection (Dihexa), and growth-factor-mediated tissue regeneration (PEG-MGF).

#pcac #fda #503a-compounding #ghk-cu #melanotan-ii #ll-37 #dihexa #peg-mgf #february-2027
Research

Nature Chemical Biology May 2026: TerminaTOR Genetically Encoded Peptide mTORC1 Inhibitor Reveals Nuclear mTORC1 Regulates CCAAT-Motif Gene Transcription in Cancer

A Nature Chemical Biology paper published May 2026 reported TerminaTOR, a genetically encoded peptide inhibitor of mTORC1 that can be targeted to specific subcellular locations and used to dissect mTORC1 biology in living cells. Targeted to the lysosome, TerminaTOR inhibits canonical lysosomal mTORC1 and induces autophagy — recapitulating rapamycin's pharmacology. Targeted to the nucleus, TerminaTOR specifically inhibits nuclear mTORC1 and reveals a previously uncharacterized regulatory function: nuclear mTORC1 controls transcription of CCAAT-motif-containing genes and promotes cancer cell proliferation. The work creates a tool for spatially separating canonical (cytoplasmic) and noncanonical (nuclear) mTORC1 functions and identifies nuclear mTORC1 as a potentially druggable axis distinct from the lysosomal pathway. Therapeutic implication: cancer programs targeting mTORC1 might benefit from nucleus-selective inhibitors that spare lysosomal autophagy.

#terminator #mtorc1 #peptide-inhibitor #nature-chemical-biology #nuclear-mtorc1 #cancer-cell-proliferation #autophagy
Research

Nature Communications May 13: Chiral Engineering of Tripeptide-Drug Conjugates Controls Liquid-Liquid Phase Separation vs β-Sheet Hydrogel Formation

A Nature Communications paper published May 13, 2026 reported that chiral engineering of tripeptide-drug conjugates (PDCs) — systematically varying the L/D amino-acid configuration in the peptide moiety — controls phase behavior between liquid-liquid phase separation (LLPS) and β-sheet-rich hydrogel formation. PDCs with alternating L/D residues underwent LLPS in solution; all-L or all-D PDCs formed structured hydrogels. The chirality-controlled phase behavior is a design lever for PDC drug-product engineering: LLPS-prone conjugates dissolve readily for parenteral dosing, while hydrogel-forming variants enable sustained-release depots or injection-site retention. The work expands the design space for peptide-drug conjugate formulation, joining the broader May 2026 PDC research cycle alongside the Avacta AVA6103 FOCUS-01 trial start and the Bicycle Therapeutics ASCO Duravelo-2 readout.

#chiral-peptide #peptide-drug-conjugate #nature-communications #liquid-liquid-phase-separation #hydrogel #formulation
Industry

SNS Insider Peptide Synthesis Market Report (May 19): Market Reaches $1.89B by 2035 — GLP-1 Demand Drives Bachem, PolyPeptide, CordenPharma SPPS Capacity Build-Out

SNS Insider published its 2026 Peptide Synthesis Market Report on Tuesday May 19, projecting the global peptide synthesis market to reach $1,889.88M by 2035 from current levels, anchored on GLP-1 receptor agonist demand and the broader peptide therapeutics pipeline. The report tracks the major SPPS capacity expansions: CordenPharma's $500M+ Boulder Colorado site adding 25,000L+ to reach 42,000L total by 2028, Bachem's three-site expansion (Bubendorf Switzerland, St Helens UK, Vista California) plus a new Sisseln Switzerland facility, and PolyPeptide's €200M credit facility supporting the doubling of 2023 revenue by 2028. The structural read: incretin-class peptide demand (semaglutide, tirzepatide, retatrutide, mazdutide, survodutide, eleglipron) plus the next-generation pipeline (NK2R agonists, amylin combos, peptide-drug conjugates) is the demand wave the CDMOs are positioning against.

#peptide-synthesis #market-report #bachem #polypeptide #cordenpharma #sns-insider #sps-capacity
Industry

Umbrella Labs Dihexa Peptide Documentation and Traceability Update (May 19) — Reference-Material Standardization Ahead of February 2027 PCAC Review

Umbrella Labs announced Tuesday May 19 a documentation and traceability update for its dihexa peptide reference material, provided strictly for laboratory developmental research use. The update is part of the company's ongoing standardization initiative focused on identity-field consistency, record continuity, and reproducibility support for research laboratories. The timing aligns with the FDA-confirmed February 2027 PCAC meeting that will review dihexa acetate for potential 503A bulks-list inclusion alongside GHK-Cu, Melanotan II, LL-37, and PEG-MGF. Dihexa is a small angiotensin IV-derived peptide originally studied at Washington State University for hepatocyte growth factor activation and neuroprotection. Reference-material traceability standards are a soft signal of the regulatory cycle compounding pharmacies and supply chains are preparing for ahead of the PCAC review.

#umbrella-labs #dihexa #reference-material #research-peptides #traceability #pcac #compounding
Industry

BSR Intelligence Peptide Industry Briefing (Mid-May 2026): Compounded Semaglutide Shipments Down 90% YoY, Tirzepatide Down 34%; Counterfeit Purity 5-75%, Lead Levels 10x Safety Limits

UK-based BSR — Biotech Scientific Research — published a peptide industry briefing covering March through early-May 2026 with concrete supply-chain and quality-control data points. Compounded semaglutide shipment volumes are down 90% year-over-year and tirzepatide down 34% as the FDA-declared shortage resolution shifts demand back to branded supply; the April 30 proposal to exclude both drugs from the 503B bulks list continues to compress the compounded segment with comments closing June 29. On the quality side, the briefing cites the 2018 falsification analysis showing research-peptide purity ranging from 5% to 75% with lead concentrations 10x safety limits, plus current evidence of fake Certificates of Analysis from Chinese-sourced products that don't match actual contents. The 'CORE PEPTIDES' scam was flagged January 2026 with documented $500 losses via Cash App and no recourse. 455+ FDA adverse-event reports for compounded semaglutide alone trace back to dosing errors from patients self-administering incorrect doses from multidose vials.

#bsr-intelligence #research-peptides #counterfeit #compounded-glp-1 #purity #fda-adverse-events #supply-chain
Industry

Compounded GLP-1 Telehealth Pricing Floor Update — Ozari's $86/Month Semaglutide Anchors the Low End as 503B Bulks-List Comments Close June 29

Tuesday's Ozari Health launch at $86/month for compounded semaglutide and $120/month for compounded tirzepatide places the platform at the low end of the compounded GLP-1 telehealth pricing band. Comparable platforms in the same market: Sesame ~$99/month, Henry Meds $129-249/month, Wisp ~$199/month, Mochi Health $129/month introductory, MD Lifestyle $99-249/month. The pricing-floor compression is colliding with the FDA's April 30 proposal to exclude semaglutide, tirzepatide, and liraglutide from the 503B bulks list — comments close June 29, with the final determination expected late Q3 2026. If the FDA's 503B proposal stands, large-scale 503B compounding ends and platforms either shift to 503A pharmacies (lower volume, higher unit cost) or wind down. The current cohort of telehealth launches at $86-129/month likely represents the cheapest US compounded GLP-1 will be before the regulatory regime tightens. Branded Wegovy and Foundayo's $25-149/month commercial-insurance copays remain the lower-cost path for insured patients; the cash-pay compounded market is what these telehealth launches are competing for.

#compounded-glp-1 #telehealth-pricing #ozari-health #sesame #henry-meds #503b-compounding #pricing-floor